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Transforming growth factor beta (TGFβ) is a major 
contributing factor to many diseases including 
progressive cancers [1]. Given the normal homeostatic 
functions of TGFβ in controlling cell proliferation, 
immune surveillance and angiogenesis, however, it is 
much less clear which cancer patients would derive 
clinical benefit from the administration of anti-TGFβ 
targeted therapy. The use of these therapies is 
complicated not only by toxicity issues, but also by 
concerns that interfering with tumour suppressive 
functions of TGFβ may ultimately exacerbate disease. 
Thus, identifying when and where TGFβ signalling 
promotes tumour progression [2] is key to the success 
of numerous approaches to block TGFβ signalling using 
a range of humanised antibodies, small molecule 
inhibitors (SMIs) and antisense oligonucleotides 
currently being evaluated in clinical trials [3]. Our 
recent data now provides insight into when these 
therapies might succeed [4]. 
To investigate when anti-TGFβ targeted therapies might 
be used appropriately, we screened cancer cell lines 
carrying defined cancer-associated genetic 
abnormalities in the RAS/RAF/MEK/ERK signalling 
pathway for sensitivity to SMIs of the TGFβ type 1 
receptor (TGFBR1). In assays specifically designed to 
measure cancer-stem cell like properties including 
clonogenicity and anchorage independent growth 
assays, we found that cells carrying mutant BRAF were 
dependent on TGFβ signalling for growth. Although 
cells carrying mutant KRAS (n=11), NRAS (n=4) and 
BRAF (n=7) all exhibit constitutive activation of the 
MAPK pathway, only mutant BRAF cells were 
universally inhibited by the TGFBR1 inhibitor. Our data 
were confirmed by siRNA knockdown of the receptor to 
ensure that the effects of the inhibitor were on-target. 
Additionally, the dependence of mutant BRAF cells on 
secreted autocrine TGFβ signalling for formation of 
xenograft tumours was demonstrated by stably 
expressing short-hairpin shRNA targeting TGFβ RNA 
in the cancer cells. The ability of these cells to establish 
tumours in mice was significantly impaired by TGFβ 
knockdown. The data suggests, therefore, that mutant 
BRAF cells are ‘hard-wired’ to depend on autocrine 
TGFβ signalling for growth in stressful conditions. The 
data also implies that the presence of  mutant  BRAF  in  
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sequenced tumour biopsies could act as a biomarker for 
stratifying patients for anti-TGFβ therapy. The 
mechanism of TGFβ-mediated tumour cell growth 
promotion remains elusive, but appears to be 
independent of canonical TGFβ signalling pathways 
involving the SMAD transcription factors and may 
involve activation of the small GTPase RHO-A.  It 
might be misleading, therefore, to use the 
phosphorylation of SMADs downstream of TGFβ 
receptor activation as an additional biomarker in tumour 
tissue biopsies to indicate the potential for TGFBR1  
inhibitor use in cancer.    
The patients most likely to benefit include melanoma 
cancer patients since mutation of BRAF is detected in 
approximately 50% of melanomas [5]. Melanoma is 
particularly prevalent, and mortality highest, in the 
aging population with more than 80% of deaths from 
melanoma occurring in people aged over 50 
(www.cancerresearch.org). The discovery of the genetic 
abnormalities associated with melanoma has resulted in 
an astonishing effort from researchers and the 
pharmaceutical industry alike to develop and test small 
molecule inhibitors of mutant BRAF (BRAFi). While 
these drugs (e.g. vemurafenib) have revolutionised 
treatment and increased patient survival, chemo-
resistance remains a significant clinical issue and the 
majority of patients relapse and die from drug-resistant 
metastatic disease. Our analysis of the effect of TGFβ 
inhibitors in both drug-naïve and vemurafenib-resistant 
patient derived cells therefore provides valuable 
information relating to when and where TGFβ inhibitors 
might be effective.  
We found that TGFBR1 inhibitors remained effective 
against vemurafenib-resistant patient derived cells. 
Furthermore, TGFβ inhibitors prevented the enhanced 
cell growth caused by paradoxical activation of the 
MAPK pathway seen in cells treated with BRAFi. 
Taken together targeting TGFβ signalling in mutant 
BRAF melanoma is predicted to inhibit tumour growth 
even in drug-resistant disease, however, the tumour cell 
microenvironment appears to impact significantly on 
inhibitor efficacy. We found that cell density reduced 
the ability of TGFBR1 inhibitors to prevent melanoma 
growth. In these less stressful conditions, melanoma 
cells were not dependent on TGFβ signalling to the 
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same extent. The addiction melanoma cells have to 
TGFβ signalling correlates with isolation and anchorage 
independence - situations encountered during tumour 
spread and outgrowth of metastasis. Using zebrafish 
xenograft models of melanoma cell metastasis we were 
able to track single fluorescently tagged cells during the 
process of migration into tail-fin tissue. As predicted, 
TGFBR1 inhibitors and TGFBR1 shRNA both reduced 
melanoma cell migration. In conclusion we envisage 
that TGFBR1 inhibitors are more likely to be effective 
in targeting cancer stem cell like properties and 
metastatic outgrowth, rather than in reducing the size of 
established tumours and the experience, so far, of 
investigators working on the clinical development of the 
TGFBR1 inhibitors  supports this idea [6]. To maximise 
the clinical potential of TGFBR1 inhibitors, therefore, 
we propose that investigations should focus on their use 
in the prevention of metastatic recurrence after reducing 
the established tumour burden by conventional surgical 
and chemotherapeutic approaches.   
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